Phio Pharmaceuticals Corp. announced on April 3, 2025, that podium presentations would be given on its two lead INTASYL product candidates, PH-762 and PH-894, at the ITOC conference. Melissa Maxwell, Phio's Director of Research and Program Management, was awarded two speaker presentations at the event, which provides a platform for exchanging the latest findings in cancer immunotherapy.
The first presentation, on April 3, 2025, focused on PH-762, an INTASYL siRNA compound targeting PD-1. This presentation highlighted its preclinical efficacy, favorable tolerability, and ongoing clinical evaluation as a neoadjuvant intratumoral therapy for cutaneous malignancies. PH-762 aims to enhance immune responses while minimizing systemic side effects.
The second presentation, scheduled for April 5, 2025, discussed PH-894, an INTASYL siRNA compound that selectively silences BRD4. This compound enhances Natural Killer (NK) cell activation and proliferation without off-target effects, presenting a promising strategy to improve adoptive cell therapy. These presentations underscore the breadth and innovative potential of Phio's INTASYL technology in immuno-oncology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.